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Background: This study compared the surgical, functional, and oncologic outcomes of robot-assisted
laparoscopic radical prostatectomy (RALP), laparoscopic radical prostatectomy (LRP), and retropubic
radical prostatectomy (RRP) in Korean men.
Methods: The study population included 864 patients who underwent radical prostatectomy for
prostate cancer in the departments of urology of ﬁve tertiary hospitals between 2010 and 2011. RALP, LRP,
and RRP perioperative, oncological, and functional outcomes as well as complications were assessed.
Medical cost data were analyzed for 682 of 864 patients.
Results: No signiﬁcant differences were found among the three groups regarding the length of stay,
biochemical recurrence, complications, and metastasis. The RALP group had a signiﬁcantly higher rate of
pelvic lymph node dissection (64.6% vs. 35.3% or 53.3%, P value <0.0001) and bilateral nerve-sparing
procedures (15.7% vs. 10.0% or 8.9%, P value <0.0001) and less blood loss (median 250 mL vs. 300 mL
or 700 mL, P value <0.0001) than the LRP and RRP groups. The 12-month continence recovery rate was
higher in the RALP group (92.1%) than in the LRP (86.5%) and RRP (84.4%) groups (P value <0.0001).
Medical costs for RALP were approximately twofold to threefold higher than those for LRP or RRP.
Conclusions: Our ﬁndings suggest that surgical and functional outcomes are better with robot-assisted
surgery than with laparoscopic or open surgery in terms of estimated blood loss and urinary continence;
however, no differences were found among groups in terms of biochemical recurrence and the rate of
complications.
© 2019 APPS& KPS, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).esiologists; BMI, body mass
node dissection; PSA, pros-
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Prostate cancer is the second most common cancer affecting
men worldwide. A total of 14,828 new prostate cancer cases and
1,840 prostate cancer deaths were expected to occur in Korea in
2015. The national crude incidence rate of prostate cancer will
likely reach 58.3 per 100,000 men, and the age-standardized inci-
dence rate, 38.1.1
Laparoscopic radical prostatectomy (LRP), which was imple-
mented in the early 1990s, not only has an overall success rate that
is comparable to retropubic radical prostatectomy (RRP) but also is
a minimally invasive procedure that shortens the length ofn open access article under the CC BY-NC-ND license (http://creativecommons.org/
Prostate International 7 (2019) 19e2420postoperative hospitalization owing to reduced estimated blood
loss and fast recovery. In addition, the oncological outcomes of LRP
are equivalent to those of RRP in terms of positive margin rates.
However, the uncomfortable postures adopted by the surgeon, the
reliance on the two-dimensional imaging, and the steep learning
curve due to the procedure's high degree of difﬁculty are some
limitations of LRP.2 On the other hand, robot-assisted laparoscopic
radical prostatectomy (RALP) introduced in 2001 allows a
comfortably seated surgeon on a console, simultaneous use of at
least two surgical instruments offering high degrees of freedom of
motion, and a three-dimensional stereoscopic camera, replicating
the steps of an RRP. However, the lack of tactile sense and high cost
are among its disadvantages.
Most studies comparing clinical outcomes between RALP and
other techniques have been conducted in white populations. Ac-
cording to a systematic literature review, RALP showed better
functional outcomes than LRP or RRP in terms of improved sexual
function and recovery of continence.3 Many previous studies have
reported not only better functional outcomes but also improved
immediate postoperative outcomes through reductions in the
length of hospitalization and estimated blood loss,4e7 although
other studies have not reported signiﬁcant differences in outcomes
among different surgical techniques.8,9 This study compared the
clinical outcomes and cost of RALP versus LRP and RRP in Korean
prostate cancer patients.2. Methods
2.1. Patients
A total of 1,228 patients who underwent radical prostatectomy
for prostate cancer in the departments of urology of ﬁve tertiary
hospitals of South Korea from January 2010 to December 2011 were
included in this retrospective study. All ﬁve hospitals were the
tertiary general hospitals in Seoul. The study population included
patients who (1) underwent RALP, LRP, or RRP for the treatment ofTable 1
Preoperative characteristics of the patients.
RALP (n ¼ 559) LRP
N % N
Age, years 68 (63e73) 71 (67e74
50e59 86 15.4 15
60e69 257 46.0 69
70e79 216 38.6 86
BMI, kg/m2 24.3 (22.7e26.2) 24.4 (22.6
<25 359 64.2 103
25 200 35.8 67
ASA classiﬁcation
1 272 48.7 46
2 274 49.0 118
3 13 2.3 6
Prostate volume 31.7 (25.5e41) 31 (23.8e
PSA level, ng/mL 6.0 (4.4e9) 6.5 (4.5e9
Gleason score 7 (6, 7) 7 (6, 7)
6 272 48.7 83
7 188 33.6 59
8e9 99 17.7 28
Clinical stage
Tx 5 0.9 17
T1 177 31.7 29
T2 272 48.7 99
T3 105 18.8 25
Data are expressed as median (interquartile range) or percent.
ASA, American Society of Anesthesiologists; BMI, body mass index; LRP, laparoscopic rad
radical prostatectomy; RRP, retropubic radical prostatectomy.prostate cancer and (2) had no prior history of prostate cancer. The
exclusion criteria were (1) history of prostate, urethra, or bladder-
related surgery; (2) absence of T1T3 or missing clinical stage;
(3) prostate-speciﬁc antigen (PSA) > 20 ng/mL; (4) Gleason biopsy
score <6; (5) history of neoadjuvant chemotherapy, neoadjuvant
hormonal therapy, or radiotherapeutics; (6) foreign patients; and/
or (7) clinical trial participants. The ﬁnal study population consisted
of 864 Koreanmen. Of these 864 patients, 559 underwent RALP,170
underwent LRP, and 135 underwent RRP.2.2. Data collection
RALP, LRP, and RRP perioperative, oncological, and functional
outcomes, as well as complications and costs, were compared
among groups. Operative time was deﬁned as the period from the
ﬁrst incision to the ﬁnal closure of the wound. The oncological
outcomes were assessed by positive surgical margin (PSM) status
and biochemical recurrence (BCR) rates. BCR was deﬁned as PSA
measurements 0.2 ng/mL. The functional outcome was conti-
nence; urinary continence was deﬁned as the absence of any
urinary leakage or the use of only one safety pad. Urinary incon-
tinence was conﬁrmed through electronic medical record data.
Complications were at least one of the following: anastomotic
leakage, bladder neck contracture, wound infection, organ injuries,
ileus, thromboembolism, inguinal hernia, urinary retention,
lymphocele.
Total medical cost data were analyzed for 682 of 864 patients.
These data were collected by reviewing the medical chart to esti-
mate total medical costs, including amounts covered by National
Health Insurance. The medical costs of radical prostatectomy pro-
cedures included costs of not only the operation but also 1 year of
postoperative management. The medical costs incurred by the
selected patients were determined from medical hospitalization
and outpatient receipts from diagnosis of disease to 1 year there-
after. The health-care receipts were separated as covered, non-
covered, and selective costs. Personal identiﬁcation keys were used(n ¼ 170) RRP (n ¼ 135) P
% N %
) 73 (68e77) <0.0001
8.8 5 3.7 <0.0001
40.6 48 35.6
50.6 82 60.7
e26.1) 24.3 (22.5e26.5) 0.9826
60.6 78 57.8 0.3236
39.4 57 42.2
27.1 30 22.2 <0.0001
69.4 98 72.6
3.5 7 5.2
41) 36.4 (26e45) 0.0141
.4) 6.2 (4.5e9.7) 0.5051
7 (6, 7) 0.2894
48.8 59 43.7 0.8673
34.7 43 31.9
16.5 33 24.4
10 12 8.9 <0.0001
17.1 60 44.4
58.2 55 40.7
14.7 8 5.9
ical prostatectomy; PSA, prostate-speciﬁc antigen; RALP, robot-assisted laparoscopic
Table 3
Oncological outcomes in the robot-assisted laparoscopic radical prostatectomy,
laparoscopic radical prostatectomy, and retropubic radical prostatectomy groups.
RALP
(n ¼ 559)
LRP
(n ¼ 170)
RRP
(n ¼ 135)
P
N % N % N %
Pathologic stage
T2a 119 21.3 25 14.7 17 12.6 0.0029
T2b 46 8.2 6 3.5 5 3.7
T2c 209 37.4 89 52.4 72 53.3
T3a 130 23.3 40 23.5 28 20.7
T3b 52 9.3 10 5.9 12 8.9
NA 3 0.5 0 d 1 0.7
Positive surgical margins
Overall 160 28.6 35 20.6 47 34.8 0.0051
pT2 73 13.1 17 10.0 24 17.8
pT3 87 15.6 18 10.6 23 17.0
Positive margin sites 160 28.6 35 20.6 47 34.8 d
Apex 82 14.7 20 11.8 22 16.3
Posterior 35 6.3 15 8.8 9 6.7
Anterior 24 4.3 17 10.0 14 10.4
Bladder 6 1.1 0 d 2 1.5
Other 77 13.8 11 6.4 20 14.8
Biochemical recurrence
12 months 90 16.1 31 18.2 29 21.5 0.3031
24 months 107 19.1 34 20.0 30 22.2 0.7030
36 months 117 20.9 34 20.0 31 23.0 0.7937
LRP, laparoscopic radical prostatectomy; RALP, robot-assisted laparoscopic radical
prostatectomy; RRP, retropubic radical prostatectomy.
Table 4
Complications, metastasis, and mortality rate in the robot-assisted laparoscopic
radical prostatectomy, laparoscopic radical prostatectomy, and retropubic radical
prostatectomy groups.
RALP
(n ¼ 559)
LRP
(n ¼ 170)
RRP
(n ¼ 135)
P
N % N % N %
Complications
<90 days 9 1.6 3 1.8 3 2.2 0.8621a)
<12 months 38 6.8 15 8.8 9 6.7 0.6399
<24 months 58 10.4 20 11.8 14 10.4 0.8705
Metastasis
<90 days 2 0.4 0 d 0 d d
<12 months 4 0.7 1 0.6 3 2.2 0.2248a)
<24 months 9 1.6 3 1.8 5 3.7 0.2946a)
Death
<90 days 0 d 0 d 0 d d
<12 months 1 0.2 0 d 0 d d
<24 months 3 0.5 0 d 0 d d
LRP, laparoscopic radical prostatectomy; RALP, robot-assisted laparoscopic radical
prostatectomy; RRP, retropubic radical prostatectomy.
a) Fisher's exact test.
J.E. Yun et al. / Clinical outcomes of prostate cancer treatment 21to block veriﬁcation of personal patient information. Costs were
measured in 2011 in US dollars (USD) and are outlined.
2.3. Statistical analysis
Baseline characteristics and clinical outcomes of RALP, LRP, and
RRP were evaluated and compared using a Chi-square test for
categorical variables and an analysis of variance for continuous
variables. Fisher's exact test was used to compare proportion of
complication and metastasis. Because the health-care cost distri-
bution curve was skewed to the right, median, minimum, and
maximumvalues are presented instead of mean values. All analyses
were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC,
USA). Reported statistical signiﬁcance levels were all two sided, and
the threshold of statistical signiﬁcance was P < 0.05.
2.4. Ethics statements
The Institutional Review Board (IRB) of the National Evidence-
based Healthcare Collaborating Agency (IRB No. NECAIRB14-002)
and each participating hospital approved this study. Because this
study was conducted retrospectively, the IRB waived the require-
ment for documentation of the patient's written informed consent.
3. Results
The preoperative characteristics of the patient's cohort accord-
ing to the surgical approach are shown in Table 1. The RALP, LRP,
and RRP groups were comparable in terms of bodymass index, PSA,
and Gleason score. The mean age was signiﬁcantly lower in the
RALP group than in the LRP or RRP group (68 years vs. 70 years or
71 years, respectively). Low-grade prostate cancers of American
Society of Anesthesiologists classiﬁcation were more frequently
reported in the RALP group (P < 0.0001).
Table 2 shows a comparison of perioperative parameters by
surgical approach. Operation time was the shortest with RRP, and
blood loss was signiﬁcantly lower with RALP (250 mL) than with
LRP (300 mL) and RRP (700 mL). Pelvic lymphadenectomy and
nerve-sparing techniques were more frequent in the RALP group
than in the LRP or RRP group. Length of hospital stay did not differ
among groups (P¼ 0.6985). The number of lymph node dissections
was the lowest with LRP. Nerve-sparing techniques were more
frequently used during RALP. The rate of early complications
(<30 days) was the lowest with RALP and highest with LRP.
The oncological outcomes are shown in Table 3. The pT3 rate
was higher in the RALP group (32.6%) than in the LRP (29.4%) or RRP
(29.6%) group. pT2a and pT2b rates were higher in the RALP group
than in the LRP and RRP groups. The lowest pT2c rate was found in
the RALP group. The PSM rate was the lowest in the LRP group
(20.6%) and highest in the RRP group. The anterior surgical margin
was the lowest in the RALP group, whereas the apex surgicalTable 2
Perioperative parameters in the robot-assisted laparoscopic radical prostatectomy, laparoscopic radical prostatectomy, and retropubic radical prostatectomy groups.
RALP (n ¼ 559) LRP (n ¼ 170) RRP (n ¼ 135) P
Operative time, min (IQR) 199.5 (167e249) 242.5 (212.5e272.5) 120 (101e160) <0.0001
Hospital stay, day (IQR) 7 (5e8) 6.5 (5e8) 6 (5e9) 0.6985
EBL, mL (IQR) 250 (150e400) 300 (150e500) 700 (600e900) <0.0001
PLND, yes (%) 361 (64.6) 60 (35.3) 72 (53.3) <0.0001
Nerve sparing, yes (%) 450 (80.5) 67 (39.4) 82 (60.7) <0.0001
Unilateral 354 (63.3) 47 (27.6) 62 (45.9)
Bilateral 88 (15.7) 17 (10.0) 12 (8.9)
Complications [<30 days (%)] 28 (5.0) 29 (17.1) 13 (9.6) 0.0006
EBL, estimated blood loss; LRP, laparoscopic radical prostatectomy; PLND, pelvic lymph node dissection; RALP, robot-assisted laparoscopic radical prostatectomy; RRP, ret-
ropubic radical prostatectomy.
Table 5
Medical costs in the robot-assisted laparoscopic radical prostatectomy, laparoscopic radical prostatectomy, and retropubic radical prostatectomy groups (Unit: USD).
RALP (n ¼ 421) LRP (n ¼ 141) RRP (n ¼ 120)
Median Min Max Median Min Max Median Min Max
Overall
Total cost 20,206 10,721 69,179 9,460 6,266 55,263 6,959 3,842 35,606
Covered 3,439 1,043 19,784 5,282 4,153 23,073 4,735 2,682 26,318
Noncovered 16,239 8,978 64,693 3,348 1,878 32,190 2,197 1,089 15,736
Hospitalization
Total cost 18,312 10,483 64,537 7,414 5,627 51,152 4,775 1,534 16,931
Covered 2,318 217 9,405 4,386 3,648 19,826 3,125 956 11,656
Noncovered 15,826 8,970 61,631 2,784 1,664 31,325 1,437 578 15,553
Outpatient
Total cost 2,286 11,152 21,643 1,673 186 9,094 2,112 485 30,918
Covered 1,290 7,226 17,742 904 167 8,706 1,477 352 23,418
Noncovered 499 3,926 12,716 387 19 3,454 605 56 7,498
Surgery cost 14,253 8,055 36,616 4,073 1,797 29,869 1,599 1,336 29,245
LRP, laparoscopic radical prostatectomy; RALP, robot-assisted laparoscopic radical prostatectomy; RRP, retropubic radical prostatectomy.
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group. There were no signiﬁcant differences in BCR according to the
surgical approach.
Safety outcomes among groups are listed in Table 4. The overall
3-year complication rates were 10.4%, 11.8%, and 10.4% in the RALP,
LRP, and RRP groups, respectively. Themost common complications
included bladder neck contracture, infection, and inguinal hernia.
The rate of long-term complications was similar among groups and
follow-up periods. Because fewmetastases or mortalities occurred,
comparison of these outcomes among surgical approaches was not
possible.
The cost of radical prostatectomy procedures, including the
operation itself and the 1-year postoperative management period,
was the highest for RALP (median 20,206 USD), followed by LRP
(median 9,460 USD) and RRP (median 6,959 USD) (Table 5). The
cost of RALP was twofold and threefold higher than that of LRP and
RRP, respectively. The cost of surgery accounted for the majority of
the medical expenses incurred in the ﬁrst year after RALP, and no
other signiﬁcant differences in cost were found among groups.
National Health Insurance did not cover the majority of expenses of
RALP, which had the highest proportion of uncovered costs (85.0%),
followed by LRP and RRP.
In terms of functional outcome, RALP showed the highest uri-
nary continence recovery rate, with 89.4% and 95.0% of patients
showing complete continence recovery at the 3-month and 3-year
follow-up assessments, respectively. Continence rates for LRP and
RRP were 80.6% and 81.5% at the 3-month assessment and 89.2%
and 89.8% at the 3-year assessment, respectively (Fig. 1). The trend
for urinary continence recovery according to the surgical approach
did not differ between follow-up periods.
4. Discussion
Results of the present multiinstitutional study suggest that RALP
has a higher continence recovery rate than LRP or RRP and is safer,
with less estimated blood loss and lower complication rates within
30 days of surgery, resulting in improved postoperative outcomes.
However, contrary to previous studies, no statistically signiﬁcant
differences were found among surgical techniques in terms of
length of hospitalization and biochemical relapse. Moreover, the
total 1-year health-care cost associated with RALP was twofold to
threefold higher than that of LRP or RRP.
Although previous studies have used slightly different deﬁni-
tions for urinary continence, recovery of continence after prosta-
tectomy is generally deﬁned as using just one or no pad per day.
Urinary incontinence is frequently reported to occur after radicalprostatectomy, and its reported prevalence varies greatly (from 4%
to 31%) according to the deﬁnition of incontinence used (no pad vs.
safety pad).3,10 The reported rate of continence recovery also varies
depending on the surgical technique used, but the continence re-
covery rate is generally higher with RALP than with LRP or RRP,
which is consistent with the ﬁndings of this study. Previous reports
have shown a continence recovery rate of more than 95% among
patients who had received RALP,11,12 and Stolzenburg et al reported
continence scores of 83.8% at 6 months and 92% at 1 year in 700
patients who underwent LRP via a peritoneal approach.13 However,
other studies have reported that RRP has a higher continence re-
covery rate than RALP.14,15 As suggested by Ficarra et al, a stan-
dardized classiﬁcation that distinguishes between not using pads
and using a safety pad should be considered in future studies.3
No statistically signiﬁcant differences among surgical tech-
niques were found for BCR rates at 12, 24, and 36 months. Our BCR
rates were similar to those reported in a systematic review and
several comparative studies.4,16e17
According to previous studies, the rates of surgery-related
complications for RRP, LRP, and RALP are 6.619.1%, 3.617.1%,
and 45%, respectively,18e20 whereas other complications, such as
transfusion and rectal or ureteral injury, were reported to be
approximately 14%.21,22 One systematic review reported that the
mean of overall complication rate after robot-assisted radical
prostatectomy was 9%.4 The overall complication rates were similar
for LRP and RALP, and only the transfusion rate was signiﬁcantly
lower with RALP in that report. In our study, in terms of safety
outcomes, RALP group had the lowest incidence of complications
within 90 days, but this difference was not signiﬁcant. Because
metastasis and mortality rates were very low in all three the
groups, a direct comparison of these outcomes was difﬁcult.
In our study, the PSM rate was the lowest in the LRP group,
followed by RALP and RRP. A previous meta-analysis also demon-
strated that PSM rates were higher with LRP than with RALP group
but similar to RRP.23 In another study, the PSM rate was signiﬁ-
cantly lower for RALP than RRP.24 Koutlidis et al reported no sig-
niﬁcant differences between RALP and LRP.25 In a systematic
review, PSM rates were similar for all analyses comparing RALP
versus RRP and RALP versus LRP.4
The total health-care cost within 1 year after the procedure was
approximately 20,206 USD per person for RALP, which was more
than double the cost of LRP or RRP. For prostate cancer, RALP pro-
vides three-dimensional stereoscopic images, offers outstanding
operational functionality, and is minimally invasive. As the patient's
demand for RALP increases, its use is also expected to increase, and
in various countries such as Japan, Hong Kong, and Denmark, RALP
Fig. 1. The ﬁgure shows the recovery rate of urinary continence in the robot-assisted laparoscopic radical prostatectomy (RALP), laparoscopic radical prostatectomy (LRP), and
retropubic radical prostatectomy groups (RRP).
J.E. Yun et al. / Clinical outcomes of prostate cancer treatment 23is being converted to beneﬁt coverage.26 Because public health-care
systems differ among countries, future evaluations of cost-
effectiveness using in-country data will be necessary.
Our ﬁndings are signiﬁcant from the perspective that this study
used patient data frommultiple institutions in Korea to analyze the
safety, effectiveness, and costs associated with RALP for prostate
cancer. However, because our study was limited by a retrospective
design and short follow-up observation period, our ﬁndings do not
fully reﬂect the clinical situation in Korea and cannot be general-
ized to all prostate cancer patients. This study has two main limi-
tations. First, the number of subjects enrolled was insufﬁcient to
make comparisons of results based on the different radical pros-
tatectomy techniques used. The subjects included in this study
consisted of those who received RALP (more than half, 65%), and
the percentages of patients undergoing RRP or LRP were low (15%
and 20%, respectively). Because baseline conditions of radical
prostatectomy were different among techniques, a subgroup anal-
ysis was performed for patients with localized prostate cancer
(below clinical stage T2), which is a major indication for radical
prostatectomy, to secure the possibility of comparison; however,
differences in baseline conditions among techniques still existed.
To compensate for this, attempts were made to compare surgical
outcomes after matching the variable that could affect outcome,
but the subject dropout rate aftermatchingwas high. Because there
were virtually no adverse events recorded, such as metastasis or
mortality, comparisons among surgical techniques were still not
possible for those variables. Second, improvement in sexual func-
tion, which is an important functional outcome variable of radical
prostatectomy, could not be veriﬁed using medical records.
Improvement in sexual function is a very subjective indicator that
requires data collection through a survey instrument with proven
validity, but because this study was retrospective in design,
assessing an improvement in sexual function among patients who
received radical prostatectomy was not possible. In the future,
veriﬁcation of improvement in sexual function through a pro-
spective study design and oncological outcomes through long-term
observations is needed.
5. Conclusion
The results are the ﬁrst to report in Korea that robot-assisted
surgery are superior to laparoscopic or open surgery in terms of
blood loss and urinary continence. No signiﬁcant differences in BCR
and overall complications were found among surgical techniques.Further prospective studies with longer follow-up duration are
needed.
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